You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Obesity Articles
Popular Obesity Articles
Highly Recommended Obesity Articles
Send a link to this page to your friends and colleagues.
Metformin for Type 2 Diabetes
British researchers say that metformin, the drug most often used to treat prediabetes and type 2 diabetes, could provide potential protection against endometrial cancer in women.
Endometrial cancer, a malignancy of the uterine lining, is the fourth most common cancer among women in the United States and United Kingdom. One of its preconditions is sometimes polycystic ovary syndrome (PCOS), a hormonal condition in which ovarian follicles fail to develop completely, often leading to irregular menstrual cycles, obesity, and excess hairiness.
Another side effect of PCOS is insulin resistance and excessive insulin production. Over the years, as scientists used metformin to control those symptoms in women with the syndrome, they noted that its long-term use also improved ovulation and menstrual cycle regularity.
Because obesity, PCOS, and diabetes are linked to an increased risk of endometrial cancer, researchers at the Warwick Medical School at the University of Warwick decided to study the effect of metformin on endometrial cancer cells. They used sera on the cells that they derived from three sources: a control group and two groups of PCOS women: one that had received no metformin treatment and one that had.
They found that the cancer cells treated with a serum from the metformin-treated group spread at a 25 percent slower rate than cells treated with non-metformin-affected sera.
The U.K. researchers said that while the results open the door to a potential metformin-based therapy for endometrial cancer, there still needs to be a comprehensive randomized trial to determine its full potential.
The research paper was published in The Journal of Clinical Endocrinology & Metabolism and is titled "Metformin Treatment Exerts Antiinvasive and Antimetastatic Effects in Human Endometrial Carcinoma Cells."
Categories: , Case Studies, Diabetes, Diabetes, Endometrial Cancer, Metformin, Obesity, Polycystic Ovary Syndrome (PCOS), Pre-Diabetes, Research, Type 2 Issues
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.

Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...